Robert P. Seifert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Robert P. Seifert has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
Joanna Chaffin
Department of Pathology Immunology and Laboratory Medicine Gainesville Florida USA
3 shared publications- Joanna Chaffin
University of Florida, Department of Pathology, Immunology, and Laboratory Medicine, Gainesville, FL, USA
2 shared publications - Adrian E. Roitberg
University of Florida
1 shared publication - Akbar Nawab
Department of Anatomy and Cell Biology
1 shared publication Alan Brock
Congenital Heart Center University of Florida Gainesville Florida USA
1 shared publication- Alexa J. Siddon
Departments of Pathology & Laboratory Medicine, Yale School of Medicine , New Haven, CT
1 shared publication
Latest Publications
- Open Access
- 12 December 2025
- Published by Elsevier in Academic Pathology
- Vol. 13 (1)
Joining the National Resident Matching Program Fellowship Match: the hematopathology experience
- 12 December 2025
- Published by Elsevier in Academic Pathology
- Vol. 13 (1)
Open AccessJoining the National Resident Matching Program Fellowship Match: the hematopathology experience
- 27 February 2025
- Published by Wiley in Cytometry Part B: Clinical Cytometry
PTK7 helps detect T lymphoblastic leukemia/lymphoma by flow cytometry
T lymphoblastic leukemia/lymphoma (T‐ALL) is a malignancy composed of proliferating T lymphoblasts. T lymphoblasts can be identified by flow cytometric analysis through the detection of aberrant antigen expression and/or immaturity marker expression. An ideal marker would be expressed brightly on T lymphoblasts but absent in mature T lymphocytes. One such marker is protein tyrosine kinase‐7 (PTK7). However, PTK7 has not been widely adopted in clinical flow cytometry labs or incorporated into any T‐ALL flow cytometry best practice recommendations. To this end, we demonstrate the utility of PTK7 in flow cytometry panels for T‐ALL diagnosis, minimal/measurable residual disease (MRD) detection, and relapse. We retrospectively evaluated flow cytometry data on 175 patients. PTK7 was classified as positive, showing a near two‐fold difference in brightness versus background mature T cells, in 87.76% of T‐ALL cases at initial diagnosis, 75% of T‐ALL at MRD, and 100% of T‐ALL at relapse. PTK7 expression remained intact in cases of CD34 and/or TdT negative T‐ALL (p = 0.992) and while expression was dimmer at MRD (72% decrease, p = 0.0313), PTK7 remained intact at relapse (33% increase, p = 0.8125). PTK7 should be included in flow cytometry panels when evaluating for T‐ALL, both at initial diagnosis, relapse, and for the presence of MRD.
- 27 February 2025
- Published by Wiley in Cytometry Part B: Clinical Cytometry
PTK7 helps detect T lymphoblastic leukemia/lymphoma by flow cytometry
T lymphoblastic leukemia/lymphoma (T‐ALL) is a malignancy composed of proliferating T lymphoblasts. T lymphoblasts can be identified by flow cytometric analysis through the detection of aberrant antigen expression and/or immaturity marker expression. An ideal marker would be expressed brightly on T lymphoblasts but absent in mature T lymphocytes. One such marker is protein tyrosine kinase‐7 (PTK7). However, PTK7 has not been widely adopted in clinical flow cytometry labs or incorporated into any T‐ALL flow cytometry best practice recommendations. To this end, we demonstrate the utility of PTK7 in flow cytometry panels for T‐ALL diagnosis, minimal/measurable residual disease (MRD) detection, and relapse. We retrospectively evaluated flow cytometry data on 175 patients. PTK7 was classified as positive, showing a near two‐fold difference in brightness versus background mature T cells, in 87.76% of T‐ALL cases at initial diagnosis, 75% of T‐ALL at MRD, and 100% of T‐ALL at relapse. PTK7 expression remained intact in cases of CD34 and/or TdT negative T‐ALL (p = 0.992) and while expression was dimmer at MRD (72% decrease, p = 0.0313), PTK7 remained intact at relapse (33% increase, p = 0.8125). PTK7 should be included in flow cytometry panels when evaluating for T‐ALL, both at initial diagnosis, relapse, and for the presence of MRD.
- 31 December 2024
- Published by Springer Nature in Annals of Hematology
- p. 1-5
Severe aplastic anemia with acquired X chromosome clonality as a sole abnormality
This case is a rare presentation of severe aplastic anemia in a 31-year-old male with acquired clonality of the X chromosome as the sole cytogenetic abnormality. This abnormality has not been reported to our knowledge, and the significance of this finding remains unclear. Comprehensive diagnostic workup included bone marrow biopsy, cytogenetic analysis, and Next-Generation sequencing, which revealed no tier I/II variants typically associated with clonal hematopoietic disorders. The patient was managed with triple immunosuppressive therapy pending hematopoietic stem cell transplant evaluation and workup. The clinical and genetic findings in this case are noteworthy for possible pre-malignant aberration, highlighting the need for further investigation into isolated chromosomal anomalies in aplastic anemia in the future.
- 31 December 2024
- Published by Springer Nature in Annals of Hematology
- p. 1-5
Severe aplastic anemia with acquired X chromosome clonality as a sole abnormality
This case is a rare presentation of severe aplastic anemia in a 31-year-old male with acquired clonality of the X chromosome as the sole cytogenetic abnormality. This abnormality has not been reported to our knowledge, and the significance of this finding remains unclear. Comprehensive diagnostic workup included bone marrow biopsy, cytogenetic analysis, and Next-Generation sequencing, which revealed no tier I/II variants typically associated with clonal hematopoietic disorders. The patient was managed with triple immunosuppressive therapy pending hematopoietic stem cell transplant evaluation and workup. The clinical and genetic findings in this case are noteworthy for possible pre-malignant aberration, highlighting the need for further investigation into isolated chromosomal anomalies in aplastic anemia in the future.
- Open Access
- 1 November 2024
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2024 (11) , rjae622
Young and naïve B cells are a diagnostic pitfall in pediatric tonsillectomies
Tonsillar marginal zone hyperplasia may mimic mucosa-associated lymphoid tissue lymphoma, a rare diagnosis in children. Histologically, both entities can demonstrate expansion of the marginal zone with disruption of follicular architecture. However, marginal zone hyperplasia may appear polyclonal by flow cytometry. We present two pediatric tonsillectomy cases with tonsillar marginal zone hyperplasia and discuss the diagnostic challenges this poses in the pediatric population. Both tonsillectomies demonstrated expansion of marginal zones with partial architectural effacement, and flow cytometric analysis of both cases detected lambda light chain restricted, CD20(bright) B cells without CD38. Authors have suggested that the lambda restricted B cells in this setting represent naïve, unmutated B cells with preferential, but polyclonal, lambda expression. Our cases are in line with this thought. While robust, BIOMED-2 primer PCR can show dominant IgK peaks, which may be misinterpreted. This presents a diagnostic pitfall in the workup of pediatric tonsils that community pathologists must consider.
- 1 November 2024
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2024 (11) , rjae622
Open AccessYoung and naïve B cells are a diagnostic pitfall in pediatric tonsillectomies
Tonsillar marginal zone hyperplasia may mimic mucosa-associated lymphoid tissue lymphoma, a rare diagnosis in children. Histologically, both entities can demonstrate expansion of the marginal zone with disruption of follicular architecture. However, marginal zone hyperplasia may appear polyclonal by flow cytometry. We present two pediatric tonsillectomy cases with tonsillar marginal zone hyperplasia and discuss the diagnostic challenges this poses in the pediatric population. Both tonsillectomies demonstrated expansion of marginal zones with partial architectural effacement, and flow cytometric analysis of both cases detected lambda light chain restricted, CD20(bright) B cells without CD38. Authors have suggested that the lambda restricted B cells in this setting represent naïve, unmutated B cells with preferential, but polyclonal, lambda expression. Our cases are in line with this thought. While robust, BIOMED-2 primer PCR can show dominant IgK peaks, which may be misinterpreted. This presents a diagnostic pitfall in the workup of pediatric tonsils that community pathologists must consider.
- 19 September 2024
- Published by Springer Nature in Journal of Hematopathology
- Vol. 17 (4) , 209-214
Pathogenic variants of mycosis fungoides identified using next-generation sequencing
Mycosis fungoides (MF), the predominant form of cutaneous T-cell lymphoma (CTCL), poses diagnostic challenges due to its clinical and histological resemblance to benign skin disorders. Delayed diagnosis contributes to therapeutic delays, prompting exploration of advanced diagnostics tools. Next-generation sequencing (NGS) may enhance disease detection by identifying pathogenic variants common to CTCL but absent in benign inflammatory disorders. We aim to discuss novel and common pathogenic variants in CTCL to enhance the utility of NGS as a diagnostic adjunct. This pilot study employed (NGS) to identify pathogenic variants in 10 MF cases. Cases were selected based on PCR-confirmed T-cell receptor clonality, with adequate DNA for NGS. GatorSeq NGS Panel, Illumina NextSeq500, and QIAGEN Clinical Insight QCI software facilitated sequencing, analysis, and variant interpretation. NGS revealed eight novel mutations in genes including HLA-DRB1, AK2, ITPKB, HLA-B, TYRO3, and CHD2. Additionally, previously reported MF-associated mutations such as DNMT3A, STAT5B, and SOCS1 (mouse study only) were detected as well. Detected variants were involved in apoptotic, NF-kB, JAK-STAT, and TCR signaling pathways, providing insights into MF pathogenesis. Mutations in genes like APC, AK2, TYRO3, and ITPKB that regulate tumor proliferation and apoptosis were noted. MF cases were associated with HLA gene mutations. NGS may enhance MF diagnosis, as the detection of pathogenic variants, particularly those known to occur in MF, favors a neoplastic diagnosis over an inflammatory diagnosis. Continuing this work may lead to the discovery of therapeutic targets.
- 19 September 2024
- Published by Springer Nature in Journal of Hematopathology
- Vol. 17 (4) , 209-214
Pathogenic variants of mycosis fungoides identified using next-generation sequencing
Mycosis fungoides (MF), the predominant form of cutaneous T-cell lymphoma (CTCL), poses diagnostic challenges due to its clinical and histological resemblance to benign skin disorders. Delayed diagnosis contributes to therapeutic delays, prompting exploration of advanced diagnostics tools. Next-generation sequencing (NGS) may enhance disease detection by identifying pathogenic variants common to CTCL but absent in benign inflammatory disorders. We aim to discuss novel and common pathogenic variants in CTCL to enhance the utility of NGS as a diagnostic adjunct. This pilot study employed (NGS) to identify pathogenic variants in 10 MF cases. Cases were selected based on PCR-confirmed T-cell receptor clonality, with adequate DNA for NGS. GatorSeq NGS Panel, Illumina NextSeq500, and QIAGEN Clinical Insight QCI software facilitated sequencing, analysis, and variant interpretation. NGS revealed eight novel mutations in genes including HLA-DRB1, AK2, ITPKB, HLA-B, TYRO3, and CHD2. Additionally, previously reported MF-associated mutations such as DNMT3A, STAT5B, and SOCS1 (mouse study only) were detected as well. Detected variants were involved in apoptotic, NF-kB, JAK-STAT, and TCR signaling pathways, providing insights into MF pathogenesis. Mutations in genes like APC, AK2, TYRO3, and ITPKB that regulate tumor proliferation and apoptosis were noted. MF cases were associated with HLA gene mutations. NGS may enhance MF diagnosis, as the detection of pathogenic variants, particularly those known to occur in MF, favors a neoplastic diagnosis over an inflammatory diagnosis. Continuing this work may lead to the discovery of therapeutic targets.
- 29 February 2024
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (2) , e14707
Epstein Barr virus‐directed T‐cell therapy for refractory EBV‐PTLD in a toddler post Orthotopic heart transplantation
Epstein–Barr Virus (EBV) is a ubiquitous herpes type virus that is associated with post‐transplant lymphoproliferative disorder (PTLD). Usual management includes reduction or cessation of immunosuppression and in some cases chemotherapy including rituximab. However, limited therapies are available if PTLD is refractory to rituximab. Several clinical trials have investigated the use of EBV‐directed T cells in rituximab‐refractory patients; however, data regarding response is scarce and inconclusive. Herein, we describe a patient with EBV‐PTLD refractory to rituximab after orthotopic heart transplantation (OHT) requiring EBV‐directed T‐cell therapy. This article aims to highlight the unique and aggressive clinical presentation and progression of PTLD with utilization of EBV‐directed T‐cell therapy for management and associated pitfalls.
- 29 February 2024
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (2) , e14707
Epstein Barr virus‐directed T‐cell therapy for refractory EBV‐PTLD in a toddler post Orthotopic heart transplantation
Epstein–Barr Virus (EBV) is a ubiquitous herpes type virus that is associated with post‐transplant lymphoproliferative disorder (PTLD). Usual management includes reduction or cessation of immunosuppression and in some cases chemotherapy including rituximab. However, limited therapies are available if PTLD is refractory to rituximab. Several clinical trials have investigated the use of EBV‐directed T cells in rituximab‐refractory patients; however, data regarding response is scarce and inconclusive. Herein, we describe a patient with EBV‐PTLD refractory to rituximab after orthotopic heart transplantation (OHT) requiring EBV‐directed T‐cell therapy. This article aims to highlight the unique and aggressive clinical presentation and progression of PTLD with utilization of EBV‐directed T‐cell therapy for management and associated pitfalls.
- Open Access
- 10 June 2023
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 134, 133-134
Central nervous system nocardiosis mimicking recurrence of diffuse large B cell lymphoma with cerebral involvement
- 10 June 2023
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 134, 133-134
Open AccessCentral nervous system nocardiosis mimicking recurrence of diffuse large B cell lymphoma with cerebral involvement
- 29 May 2023
- Published by Elsevier in Clinics In Laboratory Medicine
- Vol. 43 (3) , 485-505
Artificial Intelligence for Clinical Flow Cytometry
- 29 May 2023
- Published by Elsevier in Clinics In Laboratory Medicine
- Vol. 43 (3) , 485-505
Artificial Intelligence for Clinical Flow Cytometry
- Open Access
- 22 May 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (10)
First-in-class multifunctional TYMS nonclassical antifolate inhibitor with potent in vivo activity that prolongs survival
Although thymidylate synthase (TYMS) inhibitors have served as components of chemotherapy regimens, the currently available inhibitors induce TYMS overexpression or alter folate transport/metabolism feedback pathways that tumor cells exploit for drug resistance, limiting overall benefit. Here we report a small molecule TYMS inhibitor that i) exhibited enhanced antitumor activity as compared with current fluoropyrimidines and antifolates without inducing TYMS overexpression, ii) is structurally distinct from classical antifolates, iii) extended survival in both pancreatic xenograft tumor models and an hTS/Ink4a/Arf null genetically engineered mouse tumor model, and iv) is well tolerated with equal efficacy using either intraperitoneal or oral administration. Mechanistically, we verify the compound is a multifunctional nonclassical antifolate, and using a series of analogs, we identify structural features allowing direct TYMS inhibition while maintaining the ability to inhibit dihydrofolate reductase. Collectively, this work identifies nonclassical antifolate inhibitors that optimize inhibition of thymidylate biosynthesis with a favorable safety profile, highlighting the potential for enhanced cancer therapy.
- 22 May 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (10)
Open AccessFirst-in-class multifunctional TYMS nonclassical antifolate inhibitor with potent in vivo activity that prolongs survival
Although thymidylate synthase (TYMS) inhibitors have served as components of chemotherapy regimens, the currently available inhibitors induce TYMS overexpression or alter folate transport/metabolism feedback pathways that tumor cells exploit for drug resistance, limiting overall benefit. Here we report a small molecule TYMS inhibitor that i) exhibited enhanced antitumor activity as compared with current fluoropyrimidines and antifolates without inducing TYMS overexpression, ii) is structurally distinct from classical antifolates, iii) extended survival in both pancreatic xenograft tumor models and an hTS/Ink4a/Arf null genetically engineered mouse tumor model, and iv) is well tolerated with equal efficacy using either intraperitoneal or oral administration. Mechanistically, we verify the compound is a multifunctional nonclassical antifolate, and using a series of analogs, we identify structural features allowing direct TYMS inhibition while maintaining the ability to inhibit dihydrofolate reductase. Collectively, this work identifies nonclassical antifolate inhibitors that optimize inhibition of thymidylate biosynthesis with a favorable safety profile, highlighting the potential for enhanced cancer therapy.
- Open Access
- 2 January 2023
- Published by Springer Nature in Cureus
- Vol. 15 (1) , e33276
Pericardial Effusion: A Novel Presentation of Aplastic Anemia
Pericardial effusion is defined as the accumulation of fluid between the visceral and parietal pericardium. The underlying etiology varies as any pathology that causes pericarditis or involves the pericardium can cause effusion. In practice, the majority of pericarditis cases are idiopathic, although these are assumed to be secondary to occult viral infection or inflammatory phenomena. Malignancy, particularly the metastatic spread of noncardiac primary tumors, has been implicated as a differential in the diagnosis of pericardial effusion. Though commonly seen in solid malignancies, effusion has been reported in hematologic malignancies such as myelodysplastic syndrome (MDS), acute leukemia, and lymphoma. Nonetheless, pericardial effusions associated with hematologic conditions are extremely rare with only one case report published describing pericardial effusion secondary to immune thrombocytopenia (ITP). We herein report the first documented case, to our knowledge, of pericardial effusion as an initial clinical manifestation of aplastic anemia in a middle-aged male presenting with pancytopenia.
- 2 January 2023
- Published by Springer Nature in Cureus
- Vol. 15 (1) , e33276
Open AccessPericardial Effusion: A Novel Presentation of Aplastic Anemia
Pericardial effusion is defined as the accumulation of fluid between the visceral and parietal pericardium. The underlying etiology varies as any pathology that causes pericarditis or involves the pericardium can cause effusion. In practice, the majority of pericarditis cases are idiopathic, although these are assumed to be secondary to occult viral infection or inflammatory phenomena. Malignancy, particularly the metastatic spread of noncardiac primary tumors, has been implicated as a differential in the diagnosis of pericardial effusion. Though commonly seen in solid malignancies, effusion has been reported in hematologic malignancies such as myelodysplastic syndrome (MDS), acute leukemia, and lymphoma. Nonetheless, pericardial effusions associated with hematologic conditions are extremely rare with only one case report published describing pericardial effusion secondary to immune thrombocytopenia (ITP). We herein report the first documented case, to our knowledge, of pericardial effusion as an initial clinical manifestation of aplastic anemia in a middle-aged male presenting with pancytopenia.